Platelet survival time (PLS): thromboxane B2 (TXB2) is one of the main products of cyclooxygenase in the arachidonic acid metabolic pathway of platelets. Aspirin irreversibly inhibits the cyclooxygenase of platelets until new platelets are produced by bone marrow megakaryocytes.Therefore, observing the recovery of platelet TXB2 after taking aspirin can infer the survival time of platelets.
The shortened survival time of platelets can be seen in: ① diseases with increased platelet destruction, such as primary thrombocytopenic purpura, drug-immune thrombocytopenic purpura, post transfusion purpura, hypersplenism and systemic lupus erythematosus; ②Diseases with excessive platelet consumption, such as DIC, thrombotic thrombocytopenic purpura and hemolytic uremic syndrome; ③Hypercoagulability and thromboembolic diseases, such as myocardial infarction, angina pectoris, diabetes with vascular disease, hyperlipidemia, major surgery, cerebrovascular disease, malignant tumor, deep vein thrombosis, pulmonary embolism, heart valve repair, coronary artery transplantation and pregnancy induced hypertension syndrome; ④As an index to observe the efficacy of antiplatelet drugs.
matters needing attention
Announce
edit
(1) The blood collection tube and syringe must be silicified.(2) The platelet count measured each time must be the same, otherwise the measurement results will be affected.(3) The sensitivity of this method is low when the number of platelets is too low.
